Azenta, Inc.
AZTAHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeAzenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific,. The $1.05B market capitalization puts AZTA squarely in small-cap range for its industry. It operates through Sample Management Solutions and Multiomics segments.
Market Cap
$1.05B
Beta
1.43
P/E (TTM)
—
P/E (Fwd)
37.26
EPS (TTM)
$-2.41
EPS (Fwd)
$0.61
ROE
-6.8%
ROA
-0.6%
Cash
$380.5M
Total Debt
$55.7M
Free CF
$101.3M
52W Change
-14.1%
Annual Financials
Cash vs Debt
Azenta, Inc. holds $380.5M in cash against $55.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $101.3M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -6.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been relatively flat, moving from $555.5M (2022) to $593.8M (2025).
With cash comfortably exceeding debt, AZTA has financial flexibility that may help navigate uncertain periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Azenta, Inc. and its sector.